PPARG and fatty liver disease: Negi et al. (2021) showed that several novel flame retardants (e.g., tricresyl phosphates (TMPP, TPhP), 2-ethylhexyl diphenyl phosphate (EHDPP) and tris (1,3-dichloropropyl )phosphate (TDCIPP)) could induce lipid accumulation and enhance hepatic steatosis via PPARγ activation and increased de novo FA synthesis pathway [178].